subject: Aarkstore Enterprise - Hepatitis B - Pipeline Assessment And Market Forecasts To 2017 [print this page] Aarkstore announce a new report "Hepatitis B - Pipeline Assessment and Market Forecasts to 2017 " through its vast collection of market research report.
Hepatitis B - Pipeline Assessment and Market Forecasts to 2017"is a new report from industry analysis specialists. The report is an essential source of information and analysis on the global Hepatitis B therapeutics market. The report identifies the key trends shaping and driving the global Hepatitis B therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global Hepatitis B sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by our team of industry experts.
We estimate the global Hepatitis B (Hepatitis B) therapeutics market to be valued at $1.3bn in 2009. The market is estimated to grow up to $1.5bn in 2017, with a compound annual growth rate (CAGR) of 1.3%. This slow growth is attributed to the patent expiry of Baraclude in 2015. Growth in the Hepatitis B market will be driven by the increase in the number of patients. The US is the largest market for Hepatitis B and it contributes to approximately 50% of the global market
Scope
The scope of the report includes:
- Annualized global Hepatitis B therapeutics market revenue data from 2001 to 2009, forecast for eight years to 2017.
- Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include nucleoside analogs, nucleotide analogs, interferons and glucocorticoids.
- Analysis of the current and future market competition in the global Hepatitis B therapeutics market. The key future market players covered are Novartis, Gilead Sciences, Bristol Meyers Squibb, Hoffmann-La Roche Inc., Cytheris SA, LG Life Sciences Ltd, Enzo Biochem, Digna Biotech, Daewoong Pharma and IRX Therapeutics.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include a strategic competitor assessment, a market characterization, the unmet needs and the implications for the Hepatitis B market
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global Hepatitis B therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to affect the global Hepatitis B therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
- Whats the next big thing in the global Hepatitis B therapeutics market landscape? Identify, understand and capitalize.
